Home › Compound Library › AOD-9604

AOD-9604

Peptidesubcutaneous · inferred

Synthetic hexadecapeptide fragment (176-191) of human growth hormone. Mimics the lipolytic actions of GH without anabolic or diabetogenic effects. Extremely short serum half-life (~4 min) but triggers sustained lipolytic enzyme activation. Stimulates lipolysis and inhibits lipogenesis through a non-GH receptor mechanism. GRAS-designated for oral use in the US.

Projected serum levels — 300 mcg (≈ 0.30 mg), once daily

AOD-9604
AOD-9604 modeled serum levels, 300 mcg (≈ 0.30 mg) once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1
AOD-9604 modeled serum levels with a loading dose of 435 mcg, then 300 mcg (≈ 0.30 mg) once daily The first dose is larger so levels approach steady state faster. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 300 mcg (≈ 0.30 mg) once daily (subcutaneous).

Loading schedule: 435 mcg on day 1, then 300 mcg (≈ 0.30 mg) once daily — reaching therapeutic levels sooner.

Modeled steady state after ~1 days: peak ≈ 0.000 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Peptide
Route modeled
Subcutaneous
Model confidence
inferred
Half-life
4 min
Common dose
300 mcg (≈ 0.30 mg)
Suggested maximum
600 mcg/day
Reference dose range
150–600 mcg (single dose)
Suggested cadence
once daily

Documented interactions

  • watch
    Mirabegron (Myrbetriq) + AOD-9604 Stacked effects

    AOD-9604 and Mirabegron (Myrbetriq) both push the beta3 adrenergic in the same direction.

Serum checks 1 modeled interaction pairings for aod-9604 across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone Ng FM et al. · Hormone Research, 2000

    Demonstrated AOD9604 (PMID:11146367) stimulates lipolysis and inhibits lipogenesis in mice and rats, confirming isolated lipolytic activity of the GH (177-191) fragment without somatogenic effects.

  2. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice Heffernan M et al. · Endocrinology, 2001

    Mechanistic study (PMID:11713213) showing AOD9604 lipolytic effect requires beta(3)-AR; chronic treatment in obese mice produced fat loss without IGF-1 elevation or insulin resistance.

2 published studies referenced in the app, each with a plain-language summary.